Company Description
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024.
The company was incorporated in 2005 and is headquartered in San Mateo, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Feb 14, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Vincent J. Angotti |
Contact Details
Address: 1850 Gateway Drive, Suite 175 San Mateo, California 94404 United States | |
| Phone | 650-216-3500 |
| Website | talphera.com |
Stock Details
| Ticker Symbol | TLPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001427925 |
| ISIN Number | US00444T2096 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vincent J. Angotti | Chief Executive Officer and Director |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder and Chief Medical Officer |
| Raffi Mark Asadorian | Chief Financial Officer |
| Anil N. Dasu | Chief Engineering Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2024 | 10-K | Annual Report |
| Mar 6, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | EFFECT | Notice of Effectiveness |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 424B7 | Filing |
| Feb 9, 2024 | UPLOAD | Filing |
| Feb 6, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 29, 2024 | D | Notice of Exempt Offering of Securities |